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OBSTETRICSOmega-3 supplementation to prevent
recurrent preterm birth: a systematic
review and metaanalysis of randomized
controlled trials
Gabriele Saccone, MD; Vincenzo Berghella, MDreterm birth (PTB) remains theThe purpose of this study was to evaluate the efficacy of omega-3 supplementation
for the prevention of recurrent preterm birth (PTB) in asymptomatic singleton gestations
with previous PTB. We searched fish oil, long chain polyunsaturated fatty acids, preg-
nancy, and omega-3 in MEDLINE, OVID, Scopus, ClinicalTrials.gov, the PROSPERO In-
ternational Prospective Register of Systematic Reviews, EMBASE, and the Cochrane
Central Register of Controlled Trials from inception of each database to December 2014
with no limit for language. In addition the reference lists of all identified articles were
examined to identify studies that were not captured by electronic searches. We per-
formed a metaanalysis of randomized controlled trials of asymptomatic singleton ges-
tations with previous PTB who were assigned randomly to prophylactic omega-3
supplementation vs control (either placebo or no treatment). The primary outcome was
predefined as PTB at <37 weeks of gestation. The pooled results were reported as
relative risk (RR) with 95% confidence interval (95% CI). The protocol of this review was
registered with PROSPERO (registration number: CRD42015016371). Two randomized
controlled trials that included 1080 women were analyzed. The mean gestational age at
randomization was approximately 134 days in both groups (mean difference, 0.01 days;
95% CI,e0.13 to 0.14). Women who received omega-3 had similar rates of PTB at<37
weeks of gestation (34.5% vs 39.8%; RR, 0.81; 95% CI, 0.59e1.12) and PTB at <34
weeks of gestation (12.0% vs 15.4%; RR, 0.62; 95% CI, 0.26e1.46) compared with
control subjects. The omega-3 groups had a statistically significantly longer latency
(mean difference, 2.10 days; 95% CI, 1.98e2.22) and higher birthweight (mean dif-
ference, 102.52 g; 95% CI, 20.09e184.95) compared with control subjects; the other
secondary outcomes (which included gestational age at delivery, spontaneous PTB at
<37 and 34 weeks of gestation, admission to the intensive care unit, intraventricular
hemorrhage, necrotizing enterocolitis, sepsis, and perinatal death) were similar. Omega-
3 supplementation during pregnancy does not prevent recurrent PTB in asymptomatic
singleton gestations with previous PTB. The benefits in longer latency and higher birthP number 1 cause of perinatal death
in many countries, including the United
States.1 Women with previous PTB are
considered to be at high risk for recur-
rent PTB in a subsequent pregnancy.2
The exact mechanisms for the onset
of term or preterm labor are not
known exactly, but several biochemical
changes have been reported. Prosta-
glandin concentrations are elevated in
the maternal circulation before the
beginning of spontaneous labor,3 and
exogenous administration of prosta-
glandins induces cervical dilation and
uterine contractions.4 Omega-3 fatty
acids depress the synthesis of prosta-
glandins, but the role of omega-3 sup-
plementation in the prevention of PTB is
not yet clear.5
Randomized controlled trials (RCTs)
performed to assess whether supple-
mentation during pregnancy with poly-
unsaturated fatty acids (such as
eicosapentaenoic, docosapentaenoic,
and docosahexaenoic acids) may prevent
recurrence of PTB have shown contra-
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weight may deserve further study.
Key words: fish oil, omega-3, pregnancy, preterm birthThe aim of this metaanalysis was to
evaluate the efﬁcacy of omega-3 sup-
plementation during pregnancy in the
reduction of recurrence of PTB in
asymptomatic singleton gestations with
previous PTB.
Methods
Search strategy
We searched ﬁsh oil, long chain poly-
unsaturated fatty acids, pregnancy, andAUGUST 2015 Amomega-3 in MEDLINE, OVID, Scopus,
ClinicalTrials.gov, the PROSPERO In-
ternational Prospective Register of
Systematic Reviews, EMBASE, Science-
direct, and the Cochrane Central Regis-
ter of Controlled Trials from inception
of each database to December 2014 with
no limit for language. In addition, the
reference lists of all identiﬁed articles
were examined to identify studies that
were not captured by electronic searches.erican Journal of Obstetrics& Gynecology 135
FIGURE 1
Flow diagram
These are the studies that were identified in the
systematic review.
RCTs, randomized controlled trials.
Saccone. Omega-3 and recurrent preterm birth. Am J Obstet
Gynecol 2015.
FIGURE 2
Assessment of risk of bias
A, Summary of risk of bias for each trial. The plus sign indicates a low risk of bias; the minus sign
indicates a high risk of bias; the question mark indicates unclear risk of bias. B, Risk of bias graph
about each risk of bias item presented as percentages across all included studies.
Saccone. Omega-3 and recurrent preterm birth. Am J Obstet Gynecol 2015.
FIGURE 3
Funnel plot for assessment of publication bias
Assessment of publication bias by funnel plot: no publication bias is evident.
RR, relative risk; SE, standard error.
Saccone. Omega-3 and recurrent preterm birth. Am J Obstet Gynecol 2015.
Systematic Reviews Obstetrics ajog.orgThe electronic search and the eligibility
of the studies were assessed indepen-
dently by the authors. Differences were
resolved by discussion.
Study selection, data extraction, and
assessment of risk of bias
We included all RCTs of asymptomatic
singleton gestations with previous PTB
who were assigned randomly to prophy-
lactic treatment with either omega-
3 or control (either placebo or no
treatment). All published RCTs on
omega-3 during pregnancy were care-
fully reviewed. Exclusion criteria136 American Journal of Obstetrics& Gynecologyincludedquasirandomized trials (ie, trials
in which allocationwas done on the basis
of a pseudorandom sequence [eg, odd/
even hospital number or date of birth],
alternation), trials in women with mul-
tiple gestations, and trials in women
with intrauterine growth restrictionAUGUST 2015or gestational hypertension/preeclampsia
at the time of random assignment.
The primary outcomewas PTB at<37
weeks of gestation. Secondary outcomes
included gestational age at delivery, in-
terval from random assignment to de-
livery (ie, latency), PTB at <34 weeks
TABLE 1
Descriptive data
Variable Olsen et al 20006 Harper et al 20107
Study location Northern Europe United States
Patients, n (n/N)a 228 (108/120) 852 (434/418)
Intervention daily Docosahexaenoic acid 900 mg
and eicosapentaenoic acid
1300 mg
Docosahexaenoic acid 800 mg
and eicosapentaenoic acid
1200 mg
Control Placebo Placebo
Follow up, % 98 100
Gestational age at
random assignment, d
131.8 vs 130.5 137.2 vs 137.2
Mean age, y 29 vs 30 28 vs 27
Smoking, n/Na 50/110 vs 50/122 64/434 vs 72/418
Previous preterm
birth, n/Na
1 110/110 vs 122/122 274/434 vs 282/418
>1 0/100 vs 0/122 160/434 vs 136/418
Race, n/N
African American N/A 148/434 vs 145/418
White N/A 245/434 vs 240/418
Other N/A 41/434 vs 33/418
Primary outcome:
preterm birth, wk
<37 <37
N/A, data not reported in the trial.
a Data are presented as the number of intervention vs the number of control subjects or as total number (intervention/control).
Saccone. Omega-3 and recurrent preterm birth. Am J Obstet Gynecol 2015.
ajog.org Obstetrics Systematic Reviewsof gestation, spontaneous PTB (sPTB)
at <37 and <34 weeks’ gestation, and
neonatal outcome that included birth-
weight, admission to neonatal intensive
care unit, neonatal respiratory distress
syndrome, bronchopulmonary dyspla-
sia, intraventricular hemorrhage, ne-
crotizing enterocolitis, neonatal sepsis,
and perinatal death. All analyses were
done with an intention-to-treat ap-
proach. All authors of the included
trials were contacted for missing data.
The risk of bias in each included
study was assessed by the use of the
criteria outlined in the Cochrane Hand-
book for Systematic Reviews of In-
terventions. Review authors’ judgments
were categorized as “low risk,” “high
risk,” or “unclear risk” of bias.8
Data synthesis
The data analysis was completed inde-
pendently by the authors who used Re-
view Manager (version 5.3, 2014; The
Nordic Cochrane Centre, Cochrane
Collaboration, Copenhagen, Denmark).
Discrepancies were resolved by discus-
sion. Heterogeneity across studies was
assessed with the use of the Higgins I2
test.8 In case of statistically signiﬁcant
heterogeneity, the random effects model
of DerSimonian and Laird was used,
otherwise a ﬁxed effect model was
managed.8 The pooled results were re-
ported as relative risk (RR) or as mean
difference with 95% conﬁdence interval
(95% CI).
The protocol of this review was
registered with the PROSPERO Inter-
national Prospective Register of Sys-
tematic Reviews (registration no.
CRD42015016371). The metaanalysis
was performed according to the Pre-
ferred Reporting Item for Systematic
Reviews and Meta-analyses (PRISMA)
statement.9
Results
Study selection, study characteristics,
and risk of bias of included studies
We identiﬁed 29 trials on omega-3 sup-
plementation during pregnancy.6,7,10-36
No similar systematic reviews were
found during the search process. Two
trials that met inclusion criteria for this
metaanalysis were analyzed.6,7 The ﬂowof study identiﬁcation is shown in
Figure 1. From one of the studies, we
obtained additional and unpublished
data about PTB at <34 weeks of gesta-
tion, sPTB at <34 weeks of gestation,
and birthweight.7 The quality of RCTs
that were included in our metaanalysis
and assessed by the Cochrane Collabo-
ration’s tool revealed that both studies
had a low risk of bias (Figure 2). Risk of
publication bias was assessed by visual
inspection of the funnel plot, and the
symmetric plot suggested no publication
bias (Figure 3).
The characteristics of the included
trials are summarized in Table 1. A total
of 1080 singleton gestations with at least
1 previous PTB were included. Both
studies used daily oral docosahexaenoic
and eicosapentaenoic acids supplemen-
tation as treatment and placebo asAUGUST 2015 Amcontrol. In one of the included studies,
all participants (both intervention and
control group) received weekly intra-
muscular 17-alpha-hydroxyprogester-
one caproate 250 mg.7 Of the 1080
singleton gestations included in the 2
trials, 544 gestations (50.4%) were
assigned randomly to the omega-3 group
and 540 gestations (49.6%) were
assigned randomly to the control group.
The mean of GA at randomization was
approximately 134 days in both groups
(mean difference, 0.01 days; 95% CI,
e0.13 to 0.14).
Synthesis of results
Women who received omega-3 supple-
mentation had similar rates of PTB at
<37 weeks’ gestation (34.5% vs 39.8%;
RR, 0.81; 95% CI, 0.59e1.12; Figure 4)
and PTB<34 weeks (12.0% vs 15.4%;erican Journal of Obstetrics& Gynecology 137
FIGURE 4
Forest plot for preterm birth <37 weeks of gestation
The Forest plot gives values for preterm birth at<37 weeks of gestation. Blue square, risk ratio of the study with 95% confidence interval. Small closed
square, Olsen risk ratio. Large closed square, Harper risk ratio. Closed diamond, pooled risk ratio.
Olsen 2000.6 Harper 2010.7
CI, confidence interval; M-H, Mantel-Haenszel; PTB, preterm birth <37 weeks of gestation.
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Systematic Reviews Obstetrics ajog.orgRR, 0.62; 95% CI, 0.26e1.46) compared
with controls. The omega-3 group had
a signiﬁcantly longer latency (mean dif-
ference, 2.10 days; 95% CI 1.98e2.22)
and higher birthweight (mean differ-
ence, 102.52 g; 95% CI, 20.09e184.95)TABLE 2
Primary and secondary outcomes
Variable Olsen et al, 20006
Gestational age at
delivery mean, d
270/261
Mean latency, d 137/130
Preterm birth, n/N
<37 wk 23/108 vs 40/120
<34 wk 5/108 vs 16/120
Spontaneous preterm
birth, wk
<37 N/A
<34 N/A
Birthweight, g 3169/2960
Neonatal intensive
care unit, n/N
N/A
Intraventricular
hemorrhage, n/N
N/A
Necrotizing
enterocolitis, n/N
N/A
Sepsis, n/N N/A
Perinatal death, n/N N/A
Data are presented as the number of patients in the intervention
N/A, data not available.
a Mean difference; b Statistically significant.
Saccone. Omega-3 and recurrent preterm birth. Am J Obste
138 American Journal of Obstetrics& Gynecologycompared with control subjects; the
other secondary outcomes were similar
(Table 2).
No data about respiratory distress
syndrome and bronchopulmonary dys-
plasia were reported.Harper et al, 20107 Total
264/262 267/262
127/125 132/128
164/434 vs 174/418 187/542 (34.5%) vs 21
60/434 vs 67/418 65/542 (12.0%) vs 83/
143/434 vs 149/418 143/434 (32.9%) vs 14
51/434 vs 57/418 51/434 (11.8%) vs 57/
2858/2784 3013/2872
110/427 vs 99/410 110/427 (25.8%) vs 99
10/427 vs 9/410 10/427 (2.3%) vs 9/41
3/427 vs 4/410 3/427 (0.7%) vs 4/41
5/427 vs 3/410 5/427 (1.2%) vs 3/41
16/434 vs 17/418 16/434 (3.7%) vs 17/4
vs the number of control subjects.
t Gynecol 2015.
AUGUST 2015Comment
Main ﬁndings
This metaanalysis of the 2 RCTs that
evaluated the efﬁcacy of daily oral
omega-3 supplementation during pre-
gnancy to reduce the incidence ofRelative risk
(95% confidence interval)
5.30a (e0.97 to 11.57)
2.10a (1.98e2.22)b
4/538 (39.8%) 0.81 (0.59e1.12)
538 (15.4%) 0.62 (0.26e1.46)
9/418 (35.6%) 0.92 (0.77e1.11)
418 (13.6%) 0.86 (0.61e1.23)
102.52a (20.09e184.95)b
/410 (24.0%) 1.07 (0.84e1.35)
0 (2.2%) 1.07 (0.44e2.60)
0 (0.9%) 0.72 (0.16e3.20)
0 (0.7%) 1.60 (0.38e6.65)
18 (4.1%) 0.91 (0.46e1.77)
ajog.org Obstetrics Systematic Reviewsrecurrence PTB shows that omega-3
supplementation does not prevent re-
current PTB compared with control. We
found no statistically signiﬁcant differ-
ences in the rate of PTB and in neonatal
outcome; however, the women who
received omega-3 supplementation
during pregnancy had a longer latency
and higher birthweight. Our results
concur with previous level-1 data that
showed that omega-3 supplementation
is associated with some prolongation of
pregnancy.37 However, although statis-
tically signiﬁcant, a prolongation of
gestation of 2.1 days is unlikely to
be clinically meaningful.
Comparison with existing literature
Three other metaanalyses have evalu-
ated the efﬁcacy of omega-3 supple-
mentation during pregnancy, but none
of them analyzed women with previous
PTB.37-39 In 2006, Szajewska et al38
showed that omega-3 supplementation
could prolong the duration of low-risk
pregnancies by approximately 1.5 days.
The Cochrane Review also included
RCTs with polyunsaturated fatty acids as
control and RCTs with prostaglandin
precursor as treatment; it showed that
women who received ﬁsh oil supple-
mentation had a mean gestation age
of 2.6 days longer compared with
control subjects but that no effects were
found in the prevention of preeclam-
psia.39 Another recent metaanalysis
showed that omega-3 supplementation
during pregnancy in singleton gestations
without previous PTB, when evaluated
in the best quality RCTs or started at
<21 weeks gestation, is associated with
73% decrease in perinatal death but is
not associated with any prolongation
of gestation.37 The biologic plausibility
of the decrease in perinatal death is
not clear and could be associated with
the antiinﬂammatory effects of the
omega-3 supplementation. 37
Strengths and limitations
One of the strengths of our study is the
inclusion of only RCT data on the pre-
vention of PTB in a speciﬁc population
(ie, singleton gestations with previous
PTBs). This population represents one of
the most at risk for PTB.2,40 The 2 studiesincluded had a low risk of bias and had
the same primary outcome (ie, incidence
of PTB at<37 weeks’ gestation inwomen
with previous PTB). Both of them were
placebo-controlled, and well-designed
trials. Furthermore, the total number of
the included women was high. We ob-
tained additional and unpublished data
from one of the included studies.7
The most important limitation of
our study is that we found only 2 studies
that met the inclusion criteria; however,
the number of included women was
high. The level of dietary intake of
omega-3 could not be controlled for.
Indeed, there could be a difference in
dietary intake of omega-3 in a popula-
tion of Northern Europe6 compared
with a population in the US.7
Conclusions and implications
The biologic plausibility to explain the
efﬁcacy of omega-3 in the prevention of
PTB is not completely clear. Omega-3
could down-regulate the production of
prostaglandins E2, and studies have
showed that omega-3 fatty acidsmay have
antiinﬂammatory effects.41-43 Because
prostaglandins E2 plays a major role in
uterine contractions and in the biophys-
ical changes that are associated with cer-
vical ripening, omega-3 may delay the
initiation of cervical ripening.41-43
Based on these data, omega-3 supple-
mentation during pregnancy currently
cannot be recommended for the pre-
vention of recurrent PTB. The beneﬁts
in longer latency and higher birth-
weight may deserve further study. -
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